

Centers of Biomineralization

Maciej Pawlikowski*

Department of Mineralogy, Petrography and Geochemistry, AGH University of Science and Technology, Cracow, Poland

*Corresponding author: Maciej Pawlikowski, Department of Mineralogy, Petrography and Geochemistry, AGH University of Science and Technology, Cracow, Poland, E-mail: mpawlik@agh.edu.pl

Received: 23 Sep, 2021 | Accepted: 15 Oct, 2021 | Published: 22 Oct, 2021

Citation: Pawlikowski M (2021) Centers of Biomineralization. J Surg Open Access 7(5): dx.doi.org/10.16966/2470-0991.253

Copyright: © 2021 Pawlikowski M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

This work discusses various genetic types of tissue and organ biomineralization centers. It also addresses the issue of various substances that mineralize tissues and presents the results of attempts to dissolve the already existing biomineralization. Understanding the phenomenon of tissue biomineralization will contribute to its prevention and, if it has already occurred, its elimination.

Introduction

Biomineralization also known as calcification of tissues and organs is a process that causes many diseases and often leads to death. It has been diagnosed in arteries (including coronary vessels), heart valves, articular cartilage, tendons, skin, gallbladder, kidneys, and even in cancer, etc.

It can manifest as grains, crystals and irregular concretions, and in such cases, it is recognizable even macroscopically. Most often, however, it is hidden. Then, it results from the incorporation of elements into biological structures often damaged tissues. This hidden mineralization may or may not develop further into overt mineralization.

Two factors are necessary for the biomineralization of tissues to occur: the substance mineralizing tissues and the so-called crystallization center.

The excess of crystallizing substances in the tissues is associated with malfunctioning of the organs that produce these substances. For example, elevated cholesterol levels are the result of liver dysfunction, and elevated levels of calcium and phosphorus may be associated with disorders of the PTH, calcitonin, and vitamin D system. There are many such dependencies, dealt with by medicine in the broad sense of the word. The methods used focus on maintaining certain parameters, e.g. blood, urine, etc., within intervals considered as normal.

The second element determining the possibility of tissue biomineralization are crystallization centers. These are places in the tissues where the formation of both hidden and overt mineralization can be initiated. These places are areas of tissues subject to destruction processes. Such destruction, or damage, may result from various causes.

The presented article discusses various causes of the formation of tissue biomineralization centers. It is the result of over 40 years of the author's research and is based on extensive literature [1-51].


Definition of Tissue Biomineralization Center

Healthy and intact biological structures usually do not have surface electric potential (Figure 1.1). A tissue mineralization center is a place in the tissues where the aforementioned hidden and overt mineralization can develop. Such a place is characterized by the presence of free atomic bonds and is endowed with electric charges. Thanks to this, the center catches nearby electrically charged particles and ions. Once they are attached to the biological structure, the formation of biomineralization begins at the center.

When organic molecules are near the center, organic biomineralization occurs, such as cholesterol deposits.

When inorganic particles are near the center, inorganic biomineralization occurs, e.g. calcifications.

When there are organic and inorganic molecules near the center, they attach to the center and form an organic-inorganic biomineralization (Figure 1.2).






Figure 1.2: Examples of different tissue biomineralization.

1. Phosphate mineralization hardening the wall of the coronary artery (arrows); 2. Cross-section of the coronary artery with organic-inorganic mineralization concentrations (arrows), Scanning microscope; 3. Inorganic (phosphate) concentration in the cartilage of the hip joint (arrows); 4. A grain of inorganic mineralization in the tendon; 5. Cholesterol mineralization in the form of boat-shaped crystals in the mass of microcrystalline cholesterol. Polarizing microscope, slide stained with hematoxylin; 6. Microcrystals of inorganic mineralization on the endothelial surface of the artery in the base of the brain. Scanning microscope.

Types of Tissue Biomineralization Centers

Genetic centers of crystallization

They are the result of genetic defects that arise in many biological processes. They lead to deformation of atomic structures, e.g. in proteins, and creation of electrically charged sites in these structures (Figure 2.1). These sites are potential centers of crystallization. They can “trap” nearby charged molecules, triggering the initiation of the biomineralization process. They are passed down from generation to generation, causing hereditary tendencies to biomineralization in the same organs.

Crystallization centers resulting from excessive physical exertion

Another element that destroys tissues is excessive physical exertion exercise, sports, etc. As a result of high stress, tissues, tendons, elements of the heart, arteries, etc. may be damaged. These damaged sites are manifested by broken interatomic bonds, and consequently the formation of crystallization centers with free ionic bonds. They are endowed with electric charges that attract ions from the environment. The attracted ions built into the biological structure of the tissue are the beginning of its biomineralization (Figure 2.2).

Crystallization centers resulting from infection and inflammation

Microorganisms that infect us produce various types of toxins during their life processes. They are often extremely aggressive and cause disease symptoms. These toxins also affect tissues by damaging their structures (Figure 2.3). The result is breaking of inter atomic

bonds in the structures damaged by these toxins, i.e. formation of places that are electrically charged. The field formed around these places is the (attraction) zone for electrically charged ions, i.e. it functions as a crystallization center. In some cases, the body heals such places by itself.

Crystallization centers resulting from environmental contamination



- a. Food
- b. Water
- c. Air
- d. Radiation (various types)



Various types of substances introduced into our body with food, water or the air we breathe may lead to destruction of tissues and organs. The phenomenon is well-known, so I will not describe it here. The result of those interactions is damage to the biological structures of various organs (Figure 2.4).


Crystallization Phenomenon in the Crystallization Centers

Crystallization of organic substances

In the case when electrically charged cholesterol particles are present in the vicinity of the crystallization center, they bind to the damaged biological structure (Figure 3.1). As a result, a new biological structure is created and the tissues subject to the biomineralization process do not perform their tasks properly. That in turn causes tissue and organ dysfunction.







Crystallization of inorganic substances

If there are elevated amounts of calcium and phosphorus ions in the vicinity of the crystallization center, the process of so-called calcification begins (Figure 3.2). It contains calcium phosphates with various degrees of hydration and crystals of carbonate hydroxyapatite.

Mixed organic-inorganic crystallization

In the presence of charged organic and inorganic particles near the crystallization center, a deposit (e.g. so-called atherosclerotic plaque) is formed, built, for instance, of cholesterol and phosphates (Figures 1.1, 1.2 and 2.2).

Dissolution of Arterial Biomineralization

Dissolution of organic substances crystallizing in tissues

It is a complex procedure because organic mineralization can be multi-phase, i.e. composed of various components: fats, cholesterol, etc. Most often, the main ingredient is cholesterol. *In vitro* studies have shown [32,33] that ethyl alcohol may be one of the solvents of cholesterol. Dissolution experiments on cholesterol-filled arteries have shown that some of the cholesterol was dissolved (Figure 4.1).

Crystallization from the solution used to dissolve the deposits allowed for the crystallization of cholesterol crystals with a size of up to 0.5mm.

Dissolution of inorganic substances crystallizing in tissues

Experiments on the dissolution of inorganic (phosphate) mineralization identified in arteries, but also in other tissues, were conducted with the use of various "solvents". One of the best despite

unfavorable phosphate solubility product turned out to be water (Figure 4.2).

Dissolution of mixed organic-inorganic substances mineralizing the tissues

The most commonly recognized tissue mineralization, mixed organic-inorganic with different proportions of both components, requires complex solvents. Their use may determine the success of the dissolution process and directly improve the organ function.

Blockers of Crystallization Centers



One of the ways to combat tissue biomineralization may be the use of crystallization center blockers. These should be substances that bind to the damaged tissue in the center of crystallization, thanks to which the electric field will be eliminated, no longer "pulling" ions to mineralize the tissue.

The blocker particles should have a one-sided electric charge, thanks to which they will connect to the structure of the crystallization center (Figure 5). Their use should eliminate the electrical potential of the crystallization center, thereby eliminating the possibility of ion attachment and biomineralization.

Theoretical work on crystallization center blockers continues.

Summary

Various aspects of tissue biomineralization were presented. They maybe the basis of many new, important research works leading to both prevention of biomineralization and elimination of existing biomineralization. The importance of these studies cannot be overestimated.






Figure 4.2: 1. Diagram of detaching phosphate and calcium ions from the biological structure during dissolution of inorganic (phosphate) mineralization; 2. Degraded (partially dissolved) surface of fine crystalline phosphate mineralization. Scanning microscope.




Figure 5: Graphical image of the role of crystallization center blocker eliminating a biominerlization center.

References

1. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, et al. (1990) Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol* 15: 827-832.
2. Bertazzo S, Gentleman E (2017) Aortic valve calcification: a bone of contention. *Eur Heart J* 38: 1189-1193.
3. Bloomfield P (2002) Choice of heart valve prosthesis. *Heart* 87: 583-589.
4. Boughner DR, Thornton M, Dunmore-Buyze J, Holdsworth DW (2000) The radiographic quantitation of aortic valve calcification: implications for assessing bioprosthetic valve calcification *in vitro*. *Physiol Meas* 21: 409-416.
5. Budoff MJ, Lane KL, Bakhsheshi H, Mao S, Grassmann BO, et al. (2000) Rates of progression of coronary calcium by electron beam tomography. *Am J Cardiol* 86: 8-11.
6. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ (1998) Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. *N Engl J Med* 339: 1972-1978.
7. Ewe SH, Ng AC, Schuijff JD, van der Kley F, Colli A, et al. (2011) Location and severity of aortic valve calcium and implications for aortic regurgitation after transcatheter aortic valve implantation. *Am J Cardiol* 108: 1470-1477.
8. Gohlke-Barwolf C (2000) Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. *Heart* 86: 567-572.
9. Enriquez-Sarano M (2002) Timing of mitral valve surgery. *Heart* 87: 79-85.
10. Haensig M, Lehmkuhl L, Rastan AJ, et al. (2012) Aortic valve calcium scoring is a predictor of significant paravalvular aortic insufficiency in transapical-aortic valve implantation. *Eur J Cardiothorac Surg* 41: 1234-1241.
11. Harbaoui B, Montoy M, Charles P, Bousset L, Liebgott H, et al. (2016) Aorta calcification burden: towards an integrative predictor of cardiac outcome after transcatheter aortic valve implantation. *Atherosclerosis* 246: 161-168.
12. Herzog CA, Ma JZ, Collins AJ (2002) Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? *Circulation* 105: 1336-1341.
13. Iivanainen AM, Lindroos M, Tilvis R, Heikkilä J, Kupari M (1996) Calcific degeneration of the aortic valve in old age: is the development of flow obstruction predictable? *J Intern Med* 239: 269-273.
14. Kapila A, Hart R (1986) Calcific cerebral emboli and aortic stenosis: detection of computed tomography. *Stroke* 17: 619-621.
15. Khetarpal V, Mahajan N, Madhavan R, Batra S, Mopala P, et al. (2009) Calcific aortic valve and spontaneous embolic stroke: a review of literature. *J Neurol Sci* 287: 32-35.
16. Kizer JR, Geftter WB, deLemos AS, Scoll BJ, Wolfe ML, et al. (2001) Electron beam computed tomography for the quantification of aortic valvular calcification. *J Heart Valve Dis* 10: 361-366.
17. Kleczyński P, Dziewierz A, Daniec M, Bagiński M, Rzeszutko L, et al. (2017) Impact of post-dilatation on the reduction of paravalvular leak and mortality after transcatheter aortic valve implantation. *Kardiologia Pol* 75: 742-748.
18. Khalique OK, Hahn RT, Gada H, Nazif TM, Vahl TP, et al. (2014) Quantity and location of aortic valve complex calcification predicts severity and location of paravalvular regurgitation and frequency of post-dilatation after balloon-expandable transcatheter aortic valve replacement. *JACC Cardiovasc Interv* 7: 885-894.
19. Koos R, Mahnken AH, Dohmen G, Brehmer K, Günther RW, et al. (2011) Association of aortic valve calcification severity with the degree of aortic regurgitation after transcatheter aortic valve implantation. *Int J Cardiol* 142-145.
20. Lindblom D, Lindblom U, Qvist J, Lundström H (1990) Long-term relative survival rates after heart valve replacement. *J Am Coll Cardiol* 15: 566-573.
21. Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkilä J, et al. (1994) Factors associated with calcific aortic valve degeneration in the elderly. *Eur Heart J* 15: 865-870.
22. Mako WJ, Vesely I (1997) *In vivo* and *in vitro* models of calcification in porcine aortic valve cusps. *J Heart Valve Dis* 6: 316-323.
23. Massel D, Little SH (2001) Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. *J Am Coll Cardiol* 37: 569-578.
24. Mohler ER (2000) Are atherosclerotic processes involved in aortic-valve calcification? *Lancet* 356: 524-525.
25. Nagueh SF, Sun H, Kopelen HA, Middleton KJ, Khoury DS (2001) Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. *J Am Coll Cardiol* 37: 278-285.
26. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS (1999) Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. *N Engl J Med* 341: 142-147.
27. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD (1994) Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. *Circulation* 90: 844-853.
28. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, et al. (1997) Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. *Circulation* 95: 2262-2270.
29. Pawlikowski M (1987) Mineralizacja organizmu człowieka żyjącego (Mineralization of the living human organism). In: Wrocław Wyd. Polskiej Akademii Nauk 79: 12.
30. Pawlikowski M (1991) Mineralizacja guzów nowotworowych (Mineralization of cancer tumors). In: Szymański A (eds) *Biom mineralogia biomateriały*. PWN Warszawa: 97-102.
31. Pawlikowski M (1993) Krysztaly w organizmie człowieka (Crystals of human body). Kraków, Wydawnictwo i Drukarnia "Secesja". *Prace Mineralogiczne* 1: 32.
32. Pawlikowski M (1999) Preliminary results of dissolution of substances mineralizing human arteries. *Arch Mineralog* 52: 195-210.
33. Pawlikowski M (2003) Minerals in human blood vessels and their dissolution *in vitro*. In: Skinner HCW, Berger AW (Eds) *Geology and health*. Oxford University Press, Oxford: 155-158.
34. Pawlikowski M (2010) Biom mineralization of cancer tissues. In: Lach H (Eds) *Molecular and Physiological Aspects of Regulatory Processes of the Organism*. Wydawnictwo Abaton: 190-191.
35. Pawlikowski M (2013) Mineralization of lung cancer tumors. *Aux Sci Arch Preserv Relicts Envir Engineer*: 1-34.

36. Pawlikowski M (2014) Osteoporosis as a source of tissue mineralization. Research on osteoporosis therapy and dissolution of arterial mineralization. *J Life Sci* 8: 610-625.
37. Pawlikowski M (2016) Biomineralogy of osteoporosis. *Academia J Biotechnol* 4: 1-8.
38. Pawlikowski M (2018) Problems of Biomineralization Dissolution in Human Arteries. *Adv Card Res* 1: 68-74.
39. Pawlikowski M (2019) Blockers for Crystallization Centers. *EC Emerg Med and Critical Care* 3: 1-5.
40. Pawlikowski M (2020) Artery biomineralization and its dissolution. *ES J Cardiol* 1: 1006.
41. Pawlikowski M (2020) Tissue Biomineralization as a Mechanism Leading to Cancer Development. *J Carcinog Mutagen* 11: 347.
42. Pibarot P, Dumesnil JG (2000) Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. *J Am Coll Cardiol* 36: 1131-1141.
43. Peter M, Hoffmann A, Parker C, Lüscher T, Burckhardt D (1993) Progression of aortic stenosis. Role of age and concomitant coronary artery disease. *Chest* 103: 1715-1719.
44. Pfitzner R, Barecka D, Pawlikowski M, Kopytek M, Rudnicka-Sosin L, et al. (2018) Influence of Cryopreservation on Structural, Chemical, and Immunoenzymatic Properties of Aortic Valve Allografts. *Transplant Proc* 50: 2195-2198.
45. Piper C, Körfer R, Horstkotte D (2000) Prosthetic valve endocarditis. *Heart* 85: 590-593.
46. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS (1995) Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. *Circulation* 92: 2157-2162.
47. Ryś M, Hryniewiecki T, Michałowska I, Stokłosa P, Juraszek MR, et al. (2018) Quantitative estimation of aortic valve calcification in multislice computed tomography in predicting the development of paravalvular leaks following transcatheter aortic valve replacement. *Postepy Kardiol Interwencyjnej* 14: 85-89.
48. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, et al. (1998) Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. *J Am Coll Cardiol* 31: 126-133.
49. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, et al. (1997) Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. *J Am Coll Cardiol* 29: 630-634.
50. Takamiya Y, Miura S, Sako H, Shirai K, Morishige N, et al. (2007) Pseudoaneurysm of the mitral-aortic intervalvular fibrosa following infective endocarditis in a patient with acute heart failure: a case report. *J Cardiol* 49: 353-356.
51. Pawlikowski M, Pfitzner R (1999) Mineralization of heart, (Mineralization of heart and big blood vessels). *WydiGSMiE PAN Kraków*: 142.